Evidence supporting the use of: DHEA (dehydroepiandrosterone)
For the health condition: Addison's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

DHEA (dehydroepiandrosterone) has been investigated as an adjunct therapy in Addison's Disease, primarily based on scientific interest rather than traditional use. Addison's Disease is characterized by primary adrenal insufficiency, leading to deficiencies in glucocorticoids, mineralocorticoids, and adrenal androgens (such as DHEA). While standard therapy replaces glucocorticoids and mineralocorticoids, adrenal androgen replacement (especially DHEA) has been explored to address residual symptoms, particularly in women, such as reduced libido, impaired well-being, and decreased bone density.

Several randomized controlled trials (RCTs) and meta-analyses have evaluated DHEA supplementation in patients with Addison's Disease. Some studies demonstrate modest improvements in quality of life, mood, and sexual function, especially among women. However, the benefits are generally small, and not all patients respond. There are also concerns about androgenic side effects, such as acne and hirsutism. Major guidelines, such as those from The Endocrine Society, note that routine DHEA supplementation is not recommended but may be considered in women with persistent symptoms despite optimal steroid replacement.

In summary, the use of DHEA for Addison's Disease is supported by some scientific evidence, but the effect size is modest and not universally observed. Its use is not traditional and is not part of standard therapy, but may be considered on a case-by-case basis for selected individuals.

More about DHEA (dehydroepiandrosterone)
More about Addison's Disease